X4 PHARMACEUTICALS, INC Proceeds from Issuance of Secured Debt
X4 PHARMACEUTICALS, INC (XFOR) reported Proceeds from Issuance of Secured Debt of $20.00 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2024-11-13
- X4 PHARMACEUTICALS, INC proceeds from issuance of secured debt for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC proceeds from issuance of secured debt for the quarter ending 2023-09-30 was $22.50M.
| Period end | Proceeds from Issuance of Secured Debt 3 month | Proceeds from Issuance of Secured Debt 6 month | Proceeds from Issuance of Secured Debt 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $20.00M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $20.00M 10-Q · filed 2024-08-08 | ||
| 2023-09-30 | $22.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $22.50M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |